Tehran (IP) - The CEO of the groundbreaking medicine, Tiam Esfahani, highlighted her company's commitment to developing rare medications and announced the release of a new cancer treatment into the market following rigorous technical processes.

Iran PressIran news:  Esfahani stated, "With advancements in medicine, we have successfully met the country's medical needs." She emphasized the medicine's key features, including its availability, competitive edge against foreign counterparts, and affordability.

Moreover, Esfahani underscored that the product adheres to international standards and has received approval from the country's Food and Drug Organization.

Onkotaxel, also known as docetaxel, is a compound extracted from new tree needles and falls under the category of taxoids, a group of anti-cancer medications.

Docetaxel has shown efficacy in treating various cancers, such as breast cancer, specific types of lung cancer (non-small cell lung cancer), prostate cancer, gastric cancer, and head and neck cancer. Specific treatment regimens include:

Advanced breast cancer: Docetaxel can be administered alone or in combination with Doxorubicin, Trastuzumab, or capecitabine.

Early breast cancer: Docetaxel can be given in combination with doxorubicin and cyclophosphamide.

Lung cancer: Docetaxel may be administered alone or with cisplatin.

Prostate cancer: Docetaxel is typically combined with prednisone or prednisolone.

Metastatic gastric cancer: Docetaxel is administered alongside cisplatin and 5-fluorouracil.

Head and neck cancer: Docetaxel is used in combination with cisplatin and 5-fluorouracil.


Read More:

Health Ministry seeks to provide free treatment for cancer patients